Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Favorable prognosis in pediatric brainstem low-grade glioma - report from the German SIOP-LGG 2004 cohort.

Holzapfel J, Kandels D, Schmidt R, Pietsch T, Warmuth-Metz M, Bison B, Krauss J, Kortmann RD, Timmermann B, Thomale UW, Albert MH, Hernáiz Driever P, Witt O, Gnekow AK.

Int J Cancer. 2019 Oct 15. doi: 10.1002/ijc.32734. [Epub ahead of print]

PMID:
31613986
2.

Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004.

Boesten T, Gerber NU, Kandels D, Azizi AA, Schmidt R, Warmuth-Metz M, Pietsch T, Kortmann RD, Gnekow A, Grotzer MA.

Neurooncol Pract. 2017 Mar;4(1):29-39. doi: 10.1093/nop/npw007. Epub 2016 Dec 9.

3.

Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG).

Mirow C, Pietsch T, Berkefeld S, Kwiecien R, Warmuth-Metz M, Falkenstein F, Diehl B, von Hornstein S, Gnekow AK.

Pediatr Blood Cancer. 2014 Mar;61(3):457-63. doi: 10.1002/pbc.24729. Epub 2013 Sep 4.

PMID:
24039013
4.

Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity.

Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plasswilm L, Paulsen F, Jeremic B, Gnekow AK, Dieckmann K, Kay S, Bamberg M.

Strahlenther Onkol. 2003 Sep;179(9):585-97. Review.

PMID:
14628124
5.

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma.

Gnekow AK, Kandels D, van Tilburg C, Azizi AA, Opocher E, Stokland T, Driever PH, Meeteren AYNSV, Thomale UW, Schuhmann MU, Czech T, Goodden JR, Warmuth-Metz M, Bison B, Avula S, Kortmann RD, Timmermann B, Pietsch T, Witt O.

Klin Padiatr. 2019 May;231(3):107-135. doi: 10.1055/a-0889-8256. Epub 2019 May 20.

PMID:
31108561
6.

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.

Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF.

EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.

7.

Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.

Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Driever PH, Soerensen N, Kortmann RD, Pietsch T, Faldum A.

Neuro Oncol. 2012 Oct;14(10):1265-84. Epub 2012 Aug 31.

8.

SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings.

Hessissen L, Parkes J, Amayiri N, Mushtaq N, Sirachainan N, Anacak Y, Mitra D, Figaji A, Schouten-van Meeteren A, Sullivan M, Burger H, Davidson A, Bouffet E, Bailey S.

Pediatr Blood Cancer. 2017 Dec;64 Suppl 5. doi: 10.1002/pbc.26737.

PMID:
29297618
9.

The evolving molecular genetics of low-grade glioma.

Venneti S, Huse JT.

Adv Anat Pathol. 2015 Mar;22(2):94-101. doi: 10.1097/PAP.0000000000000049. Review. Erratum in: Adv Anat Pathol. 2015 May;22(3):226.

10.

Identification of potential biomarkers related to glioma survival by gene expression profile analysis.

Hsu JB, Chang TH, Lee GA, Lee TY, Chen CY.

BMC Med Genomics. 2019 Mar 20;11(Suppl 7):34. doi: 10.1186/s12920-019-0479-6.

11.

The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):457-79. doi: 10.1007/s11060-015-1908-9. Epub 2015 Nov 3. Review.

PMID:
26530262
12.

Craniospinal irradiation for treatment of metastatic pediatric low-grade glioma.

Tsang DS, Murphy ES, Ezell SE, Lucas JT Jr, Tinkle C, Merchant TE.

J Neurooncol. 2017 Sep;134(2):317-324. doi: 10.1007/s11060-017-2525-6. Epub 2017 Jun 17.

PMID:
28623604
13.
14.

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westphal M, Krex D, Schackert G, Tonn JC, Schlegel U, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M.

Acta Neuropathol Commun. 2019 Apr 25;7(1):59. doi: 10.1186/s40478-019-0704-8.

15.

The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):503-30. doi: 10.1007/s11060-015-1867-1. Epub 2015 Nov 3. Review.

PMID:
26530265
16.

Corpus callosum involvement and postoperative outcomes of patients with gliomas.

Chen KT, Wu TW, Chuang CC, Hsu YH, Hsu PW, Huang YC, Lin TK, Chang CN, Lee ST, Wu CT, Tseng CK, Wang CC, Pai PC, Wei KC, Chen PY.

J Neurooncol. 2015 Sep;124(2):207-14. doi: 10.1007/s11060-015-1823-0. Epub 2015 Jun 2.

PMID:
26033546
17.

Different aetiology of familial low-grade and high-grade glioma? A nationwide cohort study of familial glioma.

Malmer B, Henriksson R, Grönberg H.

Neuroepidemiology. 2002 Nov-Dec;21(6):279-86.

PMID:
12411730
18.

Glioma-associated stem cells: a novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas.

Bourkoula E, Mangoni D, Ius T, Pucer A, Isola M, Musiello D, Marzinotto S, Toffoletto B, Sorrentino M, Palma A, Caponnetto F, Gregoraci G, Vindigni M, Pizzolitto S, Falconieri G, De Maglio G, Pecile V, Ruaro ME, Gri G, Parisse P, Casalis L, Scoles G, Skrap M, Beltrami CA, Beltrami AP, Cesselli D.

Stem Cells. 2014 May;32(5):1239-53. doi: 10.1002/stem.1605.

19.

Beneficial impact of high-field intraoperative magnetic resonance imaging on the efficacy of pediatric low-grade glioma surgery.

Roder C, Breitkopf M, Ms, Bisdas S, Freitas Rda S, Dimostheni A, Ebinger M, Wolff M, Tatagiba M, Schuhmann MU.

Neurosurg Focus. 2016 Mar;40(3):E13. doi: 10.3171/2015.11.FOCUS15530.

PMID:
26926053
20.

Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.

Werner JM, Kuhl S, Stavrinou P, Röhn G, Krischek B, Blau T, Goldbrunner R, Timmer M.

Anticancer Res. 2017 Dec;37(12):6639-6648.

PMID:
29187439

Supplemental Content

Support Center